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Malignant pleural mesothelioma (MPM) is a rapidly fatal tumor
with increasing incidence worldwide responsible for many thou-
sands of deaths annually. Although there is a clear link between
exposure to asbestos and mesothelioma, and asbestos is known to
be both clastogenic and cytotoxic to mesothelial cells, the mecha-
nisms of causation of MPM remain largely unknown. However,
there is a rapidly emerging literature that describes inactivation
of a diverse array of tumor suppressor genes (TSGs) via promoter
DNA CpG methylation in MPM, although the etiology of these
alterations remains unclear. We studied the relationships among
promoter methylation silencing, asbestos exposure, patient demo-
graphics and tumor histology using a directed approach; exam-
ining six cell cycle control pathway TSGs in an incident case series
of 70 MPMs. Promoter hypermethylation of APC, CCND2,
CDKN2A, CDKN2B, HPPBP1 and RASSF1 were assessed. We
observed significantly higher lung asbestos body burden if any
of these cell cycle genes were methylated (P < 0.02), and there
was a significant trend of increasing asbestos body counts as the
number of methylated cell cycle pathway genes increased from
0 to 1 to >1 (P < 0.005). This trend of increasing asbestos body
count and increasing number of methylated cell cycle pathway
genes remained significant (P < 0.05) after controlling for age,
gender and tumor histology. These data suggest a novel tumori-
genic mechanism of action of asbestos and may contribute to the
understanding of precisely how asbestos exposure influences the
etiology and clinical course of malignant mesothelioma.
Introduction
Malignant pleural mesothelioma (MPM) is a highly lethal neoplasm
linked with asbestos exposure in 70–80% of patients. Worldwide,
the incidence of MPM is rising with 3000 cases per year reported in
the USA, 2000 cases per year in Great Britain and 500 cases per year
in Japan (1–5). The costs associated with compensation for asbestos-
related disease and asbestos remediation have been estimated at $265
billion in the USA alone over the next 40 years (6). In addition,
serious attention has recently been given to the potential contribution
of exposure to the dust from the collapse of the World Trade Center
towers in New York City to an increased risk for multiple serious
conditions including MPM (7).
Since asbestos use has been on the decline for first world nations for
20–30 years, the overall incidence of MPM is expected to peak in the
next few years in both USA and Europe (8,9). At the same time,
asbestos continues to be mined, exported and widely used in many
third world countries (10). Many nations including China, India and
some Latin American countries are still importing vast amounts of
asbestos (11,12). This fact, combined with the long 20–50 years la-
tency of MPM, virtually assures that the MPM epidemic will continue
for decades to come. This necessitates continuing research into the
molecular genetic consequences of exposure to asbestos in an effort to
better understand MPM pathogenesis, hopefully translating to pre-
vention strategies and improved patient outcomes.
The pathogenic mechanisms of asbestos contributing to the devel-
opment of MPM have long been studied, though they remain incom-
pletely characterized. Many in vitro studies have demonstrated both
clastogenic and cytotoxic effects of asbestos fibers (13,14). Phago-
cytosis of fibers by macrophages and oxidoreduction reactions on
fiber surfaces are known to generate genotoxic reactive oxygen spe-
cies that are capable of inducing DNA damage (15–17) and leading to
genetic alterations in MPM (18). In addition to genetic alterations,
the rapidly emerging literature indicates that epigenetic tumor sup-
pressor gene (TSG) silencing via promoter methylation occurs in
MPM (19–31). Methylation of cytosines in the context of promoter
CpG islands of TSGs is a well-established mechanism of stable gene
silencing in human cancers (32,33). However, the precise mecha-
nisms underlying the induction of TSG methylation and the factors
that influence tumor-specific methylation profiles are incompletely
understood. Exposure to carcinogens has been associated with TSG
methylation silencing, and recently, simultaneous examination of
multiple TSGs involved in different cellular pathways and processes
has suggested that genes are phenotypically selected for silencing.
Initial studies demonstrated that there is a dose response for methyl-
ation silencing of CDKN2A by tobacco smoke in lung cancer (34,35).
Indeed, in lung adenocarcinoma, methylation of TSGs CDKN2A and
APC also was significantly associated with exposure to tobacco
smoke (36). Dammann et al. (37) have shown that asbestos exposure
is significantly associated with methylation at CDKN2A in non-small
cell lung cancer. Suzuki et al. (21) reported that methylation of
RRAD, APPBP1, CCND2, RASSF1 and TMS1 was significantly more
prevalent in SV40-positive MPM. Furthermore, in a recent study of
28 TSG loci in MPM, Tsou et al. (31) found a significant association
between methylation of two TSGs; MT1A and MT2A with self-
reported asbestos exposure. Taken together, these data strongly sug-
gest that asbestos exposure may act to induce methylation silencing
of TSGs. However, it remains unclear if this is a direct or indirect
selection for TSG inactivation across phenotypically important path-
ways; if the process is stochastic and less phenotypically driven or
whether a dose response exists between exposure and methylation
extent. To examine this question, we have focused our efforts upon
TSGs in the cell cycle control and proliferation pathway. We studied
the APC, CCND2, CDKN2A, CDKN2B, HPPBP1 and RASSF1 genes
for promoter hypermethylation in 70 incident cases of MPM. These
genes were chosen as both a part of a larger pathway-based group of
Abbreviations: MPM, malignant pleural mesothelioma; PCR, polymerase
chain reaction; TSG, tumor suppressor gene.
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genes studied in our laboratory—in this and other types of human
cancers—and because they are generally considered among the most
important cell cycle control TSGs known to be inactivated via meth-
ylation in cancer (38–40). We examined whether methylation of spe-
cific genes, methylation at any of these loci or methylation of an
increasing number of genes was associated with asbestos exposure,
patient demographic variables or tumor histology. In this process, we
were fortunate to have quantitative asbestos burden data to explore
the relationship between exposure and epigenetic gene inactivation
in MPM.
Materials and methods
Study population
Tumor material was obtained following surgical resection at Brigham and
Women’s Hospital through the support of the International Mesothelioma
Program. All patients provided informed consent under the approval of the
appropriate Institutional Review Boards. Clinical information, including path-
ological diagnosis, was obtained from medical record review. Each patient was
assessed for history of exposure to asbestos as well as additional demographic
and environmental data by obtaining their medical and occupational history
with an in-person questionnaire or interview. Patients were followed up for
survival using the death index and last known clinic visit.
Methylation analysis
Tumor DNA was extracted from frozen tissue using the QIAamp DNA mini kit
according to the manufacturer’s protocol (Qiagen, Valencia, CA). Tumor DNA
was modified by sodium bisulfite to convert unmethylated cytosines to uracil
using the EZ DNA Methylation Kit (Zymo Research, Orange, CA) according
to the manufacturer’s protocol. Methylation-specific polymerase chain reaction
(PCR) analysis was conducted with modified template DNA as described pre-
viously (41). PCR was performed with 50 ng of modified DNA in a mixture
with 1x PCR buffer (Applied Biosystems, Foster City, CA), 0.2 mM dNTPs,
0.5 lM primers and 1.25 U of Ampli Taq Gold (Applied Biosystems) in a total
volume of 25 ll. PCR products were analyzed by electrophoresis in 3% aga-
rose gel. Sodium bisulfite-modified DNAs from circulating blood lymphocytes
of healthy control subjects, untreated and treated with SssI DNA methylase,
were used as negative and positive controls, respectively, in each run. In
addition, no template-negative controls were also present in each run. All
methylation-specific PCR reactions are optimized to detect 5% methylation
in the sample, consistent with the cutoff values generally utilized in quantita-
tive assays of methylation (42,43).
Asbestos body burden
Quantification of asbestos bodies was done using the protocol of Churg et al.
(44). Portions of normal lung tissue (1–4 g) obtained from surgery were blotted
to remove excess liquid, weighed, minced and digested with sodium hypochlo-
rite. This was mixed, vented and then sealed for 48 h. Following digestion,
samples were pelleted, resuspended in 25 ml of 50% ethanol and 10 ml of
chloroform, vortexed and 15 ml of chloroform was added. Samples were
then gently centrifuged for 10 min, supernatant was aspirated, pellets were
resuspended in 25 ml of 25% ethanol and then mixed well and filtered through
a 0.45 lm Millipore filter (Millipore, Billerica, MA). Sample tubes were
washed twice with 25 ml of 25% ethanol and filtered. Similarly, the sides of
the filter funnel were washed with 25 ml of 25% ethanol and filtered. Filters
were dehydrated, cleared twice for 1 min each in 95% ethanol, 100% ethanol
and then xylene, cut in half, recleared in xylene for another minute, mounted
on microscope slides with a counting grid using PermountTM Mounting
Medium (Fisher Scientific, Hampton, NH) and dried flat. Asbestos bodies were
then counted, and the asbestos bodies per (wet weight) gram of lung were
calculated with the following equation: number of asbestos bodies/(squares
counted  100.74  weight in grams of the digested tissue sample).
Statistical analysis
Univariate tests for association between methylation at each of the cell cycle
genes and patient demographic, tumor characteristic and exposure variables
were carried out with the appropriate statistical tests using SAS analysis soft-
ware. Similarly, tests for association between methylation at zero, one or
greater than one gene, and patient demographic, tumor characteristic and ex-
posure variables also were performed. Simple linear regression was used to test
for association between the number of methylated cell cycle genes and asbes-
tos body count. Finally, an ordered logistic model (SAS PROC PROBIT)
predicting the number of methylated cell cycle genes was used to control for
potential confounders and evaluate the contribution of asbestos body levels to
cell cycle gene methylation.
Results
A total of 83 cases had available asbestos body burden data. Among
the cases with available asbestos body counts, there were 3 extreme
outliers (14 870, 19 681 and 303 852 compared with the median
count 158) and 10 cases with zero counts. As pleural mesothelioma
arising without detectable asbestos exposure may have a distinct eti-
ology and biology, and in an effort to avoid an analysis anchored by
extreme values, we did not include tumors with zero asbestos body
counts or the extreme outliers in the analysis, restricting it to the
remaining 70 cases. We investigated the methylation status of six cell
cycle control-associated genes: CDKN2A, CDKN2B, RASSF1,
CCND2, APC and APPBP1. Exposure, demographic and tumor char-
acteristic data for these 70 cases are in presented in Table I.
The prevalence of methylation among the cell cycle control genes
varied; RASSF1 was methylated in 33% (n 5 22) of cases, APPBP1
in 20% (n 5 14), CDKN2A in 13% (n 5 9), APC and CCND2 in 9%
(n 5 6) and finally CDKN2B was methylated in 4% (n 5 3) of cases
(Figure 1). We found no significant associations between patient gen-
der or tumor histology and methylation at any of the six individual
loci examined. However, patients with RASSF1 methylation were
significantly older (65 ± 6.6 years) than patients without RASSF1
methylation (61 ± 9.5 years) (P , 0.05). We observed a similar
relationship between methylation of CCND2 and older age
Table I. Mesothelioma patient demographics and tumor characteristics
Gender, n (%)
Female 14 (20)
Male 56 (80)
Patient age
Range 30–80
Mean (SD) 62 (9.1)
Histology, n (%)
Epithelioid 54 (77)
Mixed 14 (20)
Sarcomatoid 2 (3)
Asbestos exposurea, n (%)
Yes 53 (76)
No 17 (24)
Asbestos body count
Range 6–6211
Mean (SD) 1000 (1529)
aSelf-reported.
Fig. 1. Prevalence of cell cycle control gene methylation in pleural
mesothelioma. Prevalence of methylation-positive cell cycle control genes
among pleural mesotheliomas as measured by methylation-specific PCR, and
prevalence of tumors with zero, one or more than one methylation-positive
cell cycle control gene.
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(methylated, 69 ± 8.2 years; unmethylated, 61 ± 8.9 years) (P
, 0.05). We then asked whether this relationship with age was a more
general phenomenon and found that methylation at any (one or more
gene) of the six TSGs was significantly associated with increased age
(methylated, 64 ± 8.1 years; unmethylated, 58 ± 9.4 years) (P
, 0.01). Since all these genes are involved in the process of cell cycle
control, we grouped cases into three categories; cases with no genes
methylated, cases with one gene methylated and cases with more than
one cell cycle control gene methylated. Figure 1 displays the preva-
lence of methylation of zero (40%, n 5 28), one (37%, n 5 26) or
more than one (23%, n 5 16) cell cycle pathway gene.
Next, we examined the relationship between cell cycle control gene
methylation and exposure to asbestos using both self-reported and
quantitative asbestos body counts as exposure variables. While we
found no significant associations between methylation at any one of
the six genes and self-reported asbestos exposure, cases with RASSF1
methylation had significantly higher asbestos body counts (mean
count 5 698) compared with cases without RASSF1 methylation
(mean count 5 409) (P , 0.01, Wilcoxon test). Similarly, there
was no significant relationship between methylation of any cell cycle
gene (comparing samples with no genes methylated to those with any
genes methylated) and self-reported asbestos exposure. Notably, al-
though we were unable to detect an association between self-reported
asbestos exposure and methylation of cell cycle control-related genes,
we observed a significant association between reported asbestos ex-
posure and elevated asbestos body count (P , 0.005). We also exam-
ined the relationships between asbestos body count and patient age,
gender and tumor histology. Although we did not find any association
between asbestos body count and age or histology (data not shown),
we did observe a significant difference in asbestos body count in
males (mean count 5 1218) compared with females (mean count 5
213) (P , 0.001, Wilcoxon test).
Figure 2 shows that log transformed asbestos body counts are sig-
nificantly correlated with the number of cell cycle control genes
methylated (linear regression F-test, P , 0.005). In order to control
for potential confounders of this relationship and to better represent
the discreet ordinal nature of the methylation count, we modeled the
data using an ordered logistic regression that predicts zero, one or
more than one methylated cell cycle pathway gene (Table II). This
model indicates that when controlling for gender and tumor histology,
both age and asbestos body count are significant predictors (P 5 0.04
and P , 0.05, respectively) of an increased number of methylated
cell cycle control genes.
Discussion
We evaluated promoter hypermethylation of six cell cycle control and
progression pathway genes in an incident case series of 70 MPMs
examining whether methylation of specific genes, methylation of any
of these loci or methylation of an increasing number of genes was
associated with patient demographic variables, tumor histology or
asbestos exposure. We chose to study these genes in part because they
have been studied by our laboratory as a part of a pathway-based
approach to investigating TSG methylation in other human cancers.
Further, these genes are known to be subject to inactivation by pro-
moter hypermethylation in cancer and are recognized as important in
cell cycle control and progression (38–40). We examined these genes
for methylation using methylation-specific PCR. This technique is
known to be sensitive to 5% of cells with methylation, and is there-
fore ample for detecting aberrant methylation events of phenotypic
importance (45).
Methylation of RASSF1 has been observed in 32% of MPM
(n 5 66) and previously significantly associated with SV40 exposure
(25). We observed essentially the same prevalence of RASSF1 meth-
ylation among our cases (33%), and we also found that RASSF1
methylation was significantly associated with increased asbestos body
count. Furthermore, significant, independent associations between
older patient age and methylation of CCND2 and RASSF1 were ob-
served. The association between older age and methylation is not
unexpected since it is known that CpG island hypermethylation often
increases with age (46,47). Also, in another report of TSG methyla-
tion in MPM, Toyooka et al. (25) reported prevalences of methylation
at the APC, CDKN2A and CDKN2B genes similar to ours.
One great advantage of this study was the availability of a quanti-
tative measure of asbestos exposure. Ferruginous asbestos bodies
form as a result of the interaction of macrophages with asbestos fibers,
and presence of asbestos bodies is an indicator of past exposure to
asbestos. By quantifying their level, we are able to estimate the degree
of asbestos fiber burden in an individual (48). In our data, tumors with
methylation have significantly higher asbestos exposure, using the
asbestos body counts as a quantitative measure of burden. Further-
more, there was a significant trend between increasing number of
methylated cell cycle TSGs (0 to 1 to .1) and increasing asbestos
body count. Finally, an ordered logistic regression model controlling
for gender, and tumor histology, showed that both age and an increas-
ing asbestos body count are independent significant predictors of an
increased number of methylated cell cycle pathway genes in MPM.
Table II. Ordered logistic regression model predicting increasing number of
methylated cell cycle control genes in pleural mesothelioma (n 5 70)
Predictor Estimate P-value
Age 0.67 0.04
Gender
Male 1.0 Referent
Female 0.73 0.32
Histology
Epithelioid 1.0 Referent
Mixed and sarcomatoid 0.77 0.21
Asbestos body counta 0.33 ,0.05
aScaled to: (asbestos body count per 1000).
Fig. 2. Asbestos body count versus cell cyclegene methylation. Log transformed
asbestos body count (y-axis) is plotted versus the number of methylated cell
cycle control genes (x-axis). Using simple linear regression, there is a significant
association between increasing asbestos burden and increasing number of
methylated cell cycle control genes (P , 0.005, R2 5 0.12).
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Hence, these data suggest that the induction of methylation in
a phenotypically important pathway might occur as a result of phys-
ical interaction between asbestos fibers and the parietal pleura. How-
ever, precisely how any exposure selects TSGs for silencing has only
recently begun to be explored. Maintenance of control over the cell
cycle is critical to tumor suppression, but the relationship between
dynamic carcinogen exposure and the targeting and induction of tu-
mor-specific methylation profiles is likely to be highly complex. As-
bestos exposure is associated with chronic inflammation (49), and the
physical presence of asbestos fibers at the interface of the mesothelial
membrane and the lung induces a dose-dependent cycle of death and
regrowth of mesothelial cells in the area of fiber deposition (50).
Additionally, persistent mitotic stimulation of mesothelial cells after
direct physical insult, and reactive oxygen species generated by the
fiber clearance-related cellular response, may induce a reaction by
mesothelial cells akin to that of cells in culture subject to repeated
cycles of growth. Repeated passaging of cells in tissue culture, similar
to the process of aging, is associated with the induction of TSG
silencing by promoter methylation (51). The known decades-long
latency of MPM then suggests that there is ample time for appreciable
fields of clonally altered cells to accumulate, perhaps leading to ma-
lignancy through a combination of acquired genetic and epigenetic
alterations enhanced by repeated mitotic selection. Additionally,
asbestos fibers are known to be clastogenic and lead to genotoxic
damage, and tumors with higher asbestos fiber burden may be induced
to grow faster, possibly leading to the preferential selection of
clones with silenced cell cycle control TSGs. While these mecha-
nisms of clonal selection for epigenetic silencing are consistent with
our data, it does not necessarily imply any direct asbestos fiber inter-
action with the histone/DNA methylation machinery, but instead that
the chronic inflammation response and/or accelerated tumor growth
related to asbestos burden may select for cells capable of continued
proliferation.
In summary, using a directed pathway-based approach to methyl-
ation analysis and a quantitative measure of asbestos exposure, we
observed that methylation silencing of cell cycle TSGs is associated
with both older age and asbestos exposure in MPM. Our data, using
a quantitative measure of asbestos exposure, demonstrate that epige-
netic gene inactivation is a crucial and novel mechanism for asbestos
action in the genesis of this rapidly fatal cancer.
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